Yescarta (axicabtagene ciloleucel), an autologous CD19-targeted CAR T-cell product, was the second CAR-T cell therapy approved by the FDA in 2017 for treating patients with r/r B cell lymphoma who had failed at least two rounds of systemic chemotherapy. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.